aGVHD
Conditions
Brief summary
This is a prospective study in patients receiving allogeneic stem cell transplantation. The blood samples on Day-14, -7, 0 and every 7 days until D100 were collected together with clinical data. In the final analysis, cytokines and biomarkers analysis will be carried out and compared between patients in No aGVHD and grade II-IV aGVHD.
Detailed description
This is a prospective study, observation study in patients receiving allogeneic stem cell transplantation in 4 BMT centers in Shanghai. The blood samples (on Day-14, -7, 0 and every 7 days until D100) and clinical data will be collected. In the final analysis, a panel of cytokines and biomarkers analysis of serial blood samples will be carried out and compared between patients with no aGVHD and grade II-IV aGVHD.
Interventions
None listed
Sponsors
Shanghai Jiao Tong University School of Medicine
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
16 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* all patients undergoing allogeneic stem cel transplantation * with informed consent * patients survived without aGVHD or relapse and patients with development of grade II-IV aGVHD
Exclusion criteria
* patients with blood sample and clinical data not available
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| incidence of grade II-IV aGVHD | 100 days after allogeneic stem cell tansplantation | clinical diagnosis and grade of aGVHD |
Countries
China
Contacts
Primary ContactJiong HU, M.D.
Outcome results
None listed